Science and technology | Be rich in good deeds

A new gonorrhoea drug was developed by a non-profit foundation

Antibiotics are not commercially attractive to pharmaceutical firms

Scientist studies a petri dish in clinical trial for antibiotic zoliflodacin.
Charity begins in the labImage: GARDP

GONORRHoEA IS an old affliction. The book of Leviticus mentions a contagious condition involving the continuous emission of semen and a painful erection. Only 2,500 years later, in the mid-20th century, did the discovery of antibiotics bring relief.

But not, perhaps, for long. Decades of exposure to antibiotics have led N. gonorrhoeae, the bacterium that causes the disease, to develop resistance. With few new antibiotics coming onto the market, the bug is once again gaining the upper hand. Failures of treatment are being reported in many countries. It is now designated a “priority” pathogen by the World Health Organisation.

This article appeared in the Science & technology section of the print edition under the headline "Be rich in good deeds"

Too good to be true: The contradiction at the heart of the world economy

From the November 4th 2023 edition

Discover stories from this section and more in the list of contents

Explore the edition

More from Science and technology

Archaeologists identify the birthplace of the mysterious Yamnaya

The ancient culture, which transformed Europe, was also less murderous than once thought

Producing fake information is getting easier

But that’s not the whole story, when it comes to AI


Disinformation is on the rise. How does it work?

Understanding it will lead to better ways to fight it